264 related articles for article (PubMed ID: 23349391)
1. The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys.
Schwoebel F; van Eijk LT; Zboralski D; Sell S; Buchner K; Maasch C; Purschke WG; Humphrey M; Zöllner S; Eulberg D; Morich F; Pickkers P; Klussmann S
Blood; 2013 Mar; 121(12):2311-5. PubMed ID: 23349391
[TBL] [Abstract][Full Text] [Related]
2. Iron sequestration and anemia of inflammation.
Ganz T; Nemeth E
Semin Hematol; 2009 Oct; 46(4):387-93. PubMed ID: 19786207
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats.
Theurl I; Schroll A; Sonnweber T; Nairz M; Theurl M; Willenbacher W; Eller K; Wolf D; Seifert M; Sun CC; Babitt JL; Hong CC; Menhall T; Gearing P; Lin HY; Weiss G
Blood; 2011 Nov; 118(18):4977-84. PubMed ID: 21730356
[TBL] [Abstract][Full Text] [Related]
4. Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease.
Sheetz M; Barrington P; Callies S; Berg PH; McColm J; Marbury T; Decker B; Dyas GL; Truhlar SME; Benschop R; Leung D; Berg J; Witcher DR
Br J Clin Pharmacol; 2019 May; 85(5):935-948. PubMed ID: 30677788
[TBL] [Abstract][Full Text] [Related]
5. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin.
Nemeth E; Rivera S; Gabayan V; Keller C; Taudorf S; Pedersen BK; Ganz T
J Clin Invest; 2004 May; 113(9):1271-6. PubMed ID: 15124018
[TBL] [Abstract][Full Text] [Related]
6. Inflammation-induced hepcidin is associated with the development of anemia and coronary artery lesions in Kawasaki disease.
Kuo HC; Yang YL; Chuang JH; Tiao MM; Yu HR; Huang LT; Yang KD; Chang WC; Lee CP; Huang YH
J Clin Immunol; 2012 Aug; 32(4):746-52. PubMed ID: 22392047
[TBL] [Abstract][Full Text] [Related]
7. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation.
Sun CC; Vaja V; Babitt JL; Lin HY
Am J Hematol; 2012 Apr; 87(4):392-400. PubMed ID: 22290531
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production.
Hashizume M; Uchiyama Y; Horai N; Tomosugi N; Mihara M
Rheumatol Int; 2010 May; 30(7):917-23. PubMed ID: 19639319
[TBL] [Abstract][Full Text] [Related]
9. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation.
Ganz T
Blood; 2003 Aug; 102(3):783-8. PubMed ID: 12663437
[TBL] [Abstract][Full Text] [Related]
10. Rheumatoid anemia.
Masson C
Joint Bone Spine; 2011 Mar; 78(2):131-7. PubMed ID: 20851655
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease.
Song SN; Tomosugi N; Kawabata H; Ishikawa T; Nishikawa T; Yoshizaki K
Blood; 2010 Nov; 116(18):3627-34. PubMed ID: 20644113
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment with CO-releasing molecules suppresses hepcidin expression during inflammation and endoplasmic reticulum stress through inhibition of the STAT3 and CREBH pathways.
Shin DY; Chung J; Joe Y; Pae HO; Chang KC; Cho GJ; Ryter SW; Chung HT
Blood; 2012 Mar; 119(11):2523-32. PubMed ID: 22262759
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation.
Steinbicker AU; Sachidanandan C; Vonner AJ; Yusuf RZ; Deng DY; Lai CS; Rauwerdink KM; Winn JC; Saez B; Cook CM; Szekely BA; Roy CN; Seehra JS; Cuny GD; Scadden DT; Peterson RT; Bloch KD; Yu PB
Blood; 2011 May; 117(18):4915-23. PubMed ID: 21393479
[TBL] [Abstract][Full Text] [Related]
14. Anemia of inflammation: the cytokine-hepcidin link.
Andrews NC
J Clin Invest; 2004 May; 113(9):1251-3. PubMed ID: 15124013
[TBL] [Abstract][Full Text] [Related]
15. Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans.
van Eijk LT; John AS; Schwoebel F; Summo L; Vauléon S; Zöllner S; Laarakkers CM; Kox M; van der Hoeven JG; Swinkels DW; Riecke K; Pickkers P
Blood; 2014 Oct; 124(17):2643-6. PubMed ID: 25163699
[TBL] [Abstract][Full Text] [Related]
16. Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs.
Rivera S; Nemeth E; Gabayan V; Lopez MA; Farshidi D; Ganz T
Blood; 2005 Sep; 106(6):2196-9. PubMed ID: 15933050
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Lactoferrin Oral Administration in the Treatment of Anemia and Anemia of Inflammation in Pregnant and Non-pregnant Women: An Interventional Study.
Lepanto MS; Rosa L; Cutone A; Conte MP; Paesano R; Valenti P
Front Immunol; 2018; 9():2123. PubMed ID: 30298070
[TBL] [Abstract][Full Text] [Related]
18. Autocrine formation of hepcidin induces iron retention in human monocytes.
Theurl I; Theurl M; Seifert M; Mair S; Nairz M; Rumpold H; Zoller H; Bellmann-Weiler R; Niederegger H; Talasz H; Weiss G
Blood; 2008 Feb; 111(4):2392-9. PubMed ID: 18073346
[TBL] [Abstract][Full Text] [Related]
19. A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia.
Vadhan-Raj S; Abonour R; Goldman JW; Smith DA; Slapak CA; Ilaria RL; Tiu RV; Wang X; Callies S; Cox J; Tuttle JL; Lau YK; Roeland EJ
J Hematol Oncol; 2017 Mar; 10(1):73. PubMed ID: 28327200
[TBL] [Abstract][Full Text] [Related]
20. Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation.
Roy CN; Mak HH; Akpan I; Losyev G; Zurakowski D; Andrews NC
Blood; 2007 May; 109(9):4038-44. PubMed ID: 17218383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
